Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of HRS9531 in Healthy Subjects and Subjects With Impaired Renal Function
NCT06246175Phase 1Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Feb 2024
- Primary completion
- Sep 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HRS9531 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to T(last) at Day 29, Maximum Concentration at Day 29 and 1 more. Started Feb 2024; status: completed.
02
Drugs
HRS9531
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06246175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06246175.